(NASDAQ: SMMT) Summit Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Summit Therapeutics's earnings in 2025 is -$921,617,000.On average, 18 Wall Street analysts forecast SMMT's earnings for 2025 to be -$898,095,478, with the lowest SMMT earnings forecast at -$1,079,739,457, and the highest SMMT earnings forecast at -$359,565,746. On average, 17 Wall Street analysts forecast SMMT's earnings for 2026 to be -$598,159,579, with the lowest SMMT earnings forecast at -$1,138,103,752, and the highest SMMT earnings forecast at -$312,665,866.
In 2027, SMMT is forecast to generate -$607,911,777 in earnings, with the lowest earnings forecast at -$1,232,945,731 and the highest earnings forecast at -$343,932,453.